Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
GILD vs JNJ: Momentum at Gilead Sciences Compared to Stability at Johnson & Johnson

GILD vs JNJ: Momentum at Gilead Sciences Compared to Stability at Johnson & Johnson

Key Takeaways

  • GILD (Gilead Sciences) has re-accelerated core revenue growth, led by its HIV franchise, and recently traded near all-time highs, while JNJ (Johnson & Johnson) pairs strong oncology growth with a diversified pharma-plus-medtech model.
  • Both stocks have outperformed the broader market over the past year, but GILD's growth re-acceleration and upward trend momentum currently stand out in this stock comparison.
  • JNJ carries durable headwinds, including loss of exclusivity (LOE) on Stelara and a slower-growing MedTech segment, alongside a large one-time talc litigation charge.
  • GILD trades at a relatively modest forward valuation with a roughly 2% dividend yield, while JNJ commands a richer multiple as a 64-year "Dividend King" with steady payout growth.
  • Tickeron AI Verdict: GILD — the AI-driven framework currently favors GILD for stronger trend consistency and clearer near-term growth catalysts.
  • For more context, explore GILD Major News and GILD Today's Price Move, as well as JNJ Major News and JNJ Today's Price Move.
  • Interested in automated stock selection? Browse Tickeron's Trending AI Robots for curated trading strategies.

Why Compare These Two Healthcare Names

Investors comparing large-cap healthcare stocks often weigh growth against stability. GILD and JNJ both sit near the top of the healthcare sector, yet they offer very different risk-and-return profiles. Gilead is a focused biopharmaceutical company built around antivirals and oncology, while Johnson & Johnson is a diversified healthcare conglomerate spanning pharmaceuticals and medical technology. This stock comparison is relevant for traders evaluating relative performance and momentum, as well as long-term investors weighing dividend reliability against growth re-acceleration. Understanding their recent price behavior, catalysts, and market positioning can help clarify which name is better suited to current conditions. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.

Gilead Sciences Overview and Recent Performance

Gilead Sciences is a research-based biopharmaceutical company focused on viral diseases, inflammatory and fibrotic conditions, and oncology. Its HIV portfolio, including Biktarvy and the pre-exposure prophylaxis (PrEP) treatment Yeztugo, remains the primary revenue engine, complemented by liver-disease medicines and oncology products such as Trodelvy.

Recent market activity has been notably strong. The stock climbed to new all-time highs in recent weeks and has appreciated roughly 38% year to date, outperforming the S&P 500. The latest quarterly results showed revenue above consensus, with core business growth near 16% — the fastest in more than a decade — driven by double-digit gains in HIV and liver disease. Management raised full-year guidance, and several analysts lifted price targets. One caveat: declining sales of Veklury, the legacy COVID-19 antiviral, continue to mask the underlying strength of the core portfolio, and reported (GAAP) earnings were pressured by a large non-cash charge. With a forward price-to-earnings (P/E) ratio near 17 and a dividend yield around 2%, GILD's valuation remains relatively modest versus the broader market. From what I see, the upward estimate revisions add to the constructive picture here.

Johnson & Johnson Overview and Recent Performance

Johnson & Johnson operates through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Its oncology franchise is the primary growth driver, led by Darzalex, Carvykti, Tecvayli, and Rybrevant, supported by immunology and neuroscience products such as Tremfya, Spravato, and Caplyta.

Recent performance reflects this two-speed dynamic. The stock has rallied strongly and is up roughly 30% or more year to date, aided by better-than-expected third-quarter earnings and an upward revision to full-year guidance. Innovative Medicine delivered high-single-digit growth, while MedTech expanded at a slower low-single-digit pace amid competitive pressure in electrophysiology and volume-based procurement headwinds in China. The period also featured a large one-time charge tied to a proposed resolution of long-running talc litigation, which depressed reported earnings despite solid adjusted results. Meanwhile, the loss of exclusivity on the blockbuster drug Stelara remains an ongoing drag. On the innovation front, JNJ received authorization for its OTTAVA robotic surgical system and agreed to acquire Ollin Biosciences for $2.2 billion to expand its eye-disease pipeline. I’m watching this closely because the litigation overhang could linger.

Head-to-Head Comparison

The clearest contrast is business structure. GILD is a concentrated biopharma play, where a handful of HIV and oncology products drive results, giving it higher sensitivity to individual drug momentum but a focused growth narrative. JNJ is a diversified healthcare giant whose MedTech segment provides ballast but also drags on growth when device demand softens.

On growth drivers, GILD's core business is re-accelerating into the double digits, while JNJ's pharmaceutical growth is partially offset by Stelara's loss of exclusivity and a sluggish MedTech business. On risk, GILD faces pipeline concentration and some insider selling, whereas JNJ carries litigation overhang, patent cliffs, and international pricing pressure. On valuation and income, both yield near 2%, but GILD trades at a lower forward multiple, while JNJ's 64-year dividend streak signals greater payout durability. On market sentiment, both have outperformed the market, though GILD's momentum to all-time highs reflects a cleaner, more immediate catalyst set.

Tickeron AI Verdict

Based on observable factors — trend consistency, growth re-acceleration, and relative positioning — Tickeron's AI framework would currently lean toward GILD. The stock's sustained uptrend into new highs, double-digit core growth, and upward estimate revisions suggest more favorable momentum and a clearer catalyst path than JNJ, which continues to absorb patent-cliff and litigation-related friction. That said, JNJ's diversification and dividend record give it a stability advantage. The verdict is therefore probabilistic: GILD appears better positioned for trend-following and momentum-oriented strategies in the current environment, while JNJ may appeal more to risk-averse, income-focused investors.

Exploring AI Tools for Deeper Analysis

In my view, incorporating systematic tools can add useful perspective when comparing names like these. I often turn to Tickeron’s AI Trading Bots to test how different automated strategies might have performed on GILD and JNJ across varying market conditions. The platform lets users review performance statistics, trade frequency, and risk profiles for hundreds of bots, helping identify approaches that align with a given thesis without replacing individual judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GILD, JNJ

GILD's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for GILD moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 instances where the indicator moved out of the overbought zone. In 24 of the 39 cases the stock moved lower in the days that followed. This puts the odds of a move down at 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 22 of 62 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 35%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GILD as a result. In 38 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 44%.

The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 17 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 31%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 215 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 165 of 269 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.495) is normal, around the industry mean (-1.421). GILD's P/E Ratio (-63.943) is considerably lower than the industry average of (21.700). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -11%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -5%. OGN experienced the highest price growth at 0%, while SCLX experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 26%. For the same stocks of the Industry, the average monthly volume growth was 14% and the average quarterly volume growth was 33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 33
Price Growth Rating: 46
SMR Rating: 59
Profit Risk Rating: 59
Seasonality Score: 17 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutic products and treatments for life threatening diseases

Industry PharmaceuticalsMajor

Industry
Biotechnology
Address
333 Lakeside Drive
Phone
+1 650 574-3000
Employees
17000
Web
https://www.gilead.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.